Desloracell

Quick links to important sections

Desloracell

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Desloracell

Quick Facts

Property Description
Active ingredient Desloratadine
Form Tablet, Oral Solution (Syrup)
Pharmacological class Second-Generation Antihistamine; H1-Receptor Antagonist
Common use Systemic relief from allergic conditions
Origin Synthetic metabolite of Loratadine

Desloracell: Classification and Active Composition

Desloracell is a prescription-only pharmaceutical product containing the active ingredient desloratadine, which is classified as a second-generation antihistamine and a selective H1-receptor antagonist. This medication is a single-ingredient product utilized to counteract effects associated with allergic responses. Desloratadine is recognized as the primary active metabolite of the older compound, loratadine, reflecting an advanced chemical profile. This chemical structure limits its ability to cross the blood-brain barrier. This characteristic is key to its designation as a non-sedating agent, a valuable clinical property that distinguishes it from older allergy treatments.


Forms, Differentiation, and General Purpose

Manufactured for oral administration, Desloracell is supplied in various high-level dosage forms, including the standard oral tablet and the oral solution (syrup), offering flexibility for different patient groups. The general purpose of Desloracell is to provide sustained systemic relief from the discomfort associated with various allergic conditions. It achieves this by selectively inhibiting the activity of histamine, a substance released during allergic reactions that causes symptoms such as itching and mucosal swelling. The medicine is commonly employed in managing situations like severe seasonal allergy symptoms, providing effective and reliable symptomatic support without the significant interference with daily activities often associated with sedating antihistamines.

Regulatory References

  1. U.S. National Library of Medicine
  2. NIH MedlinePlus
  3. European Medicines Agency

What side effects are possible with Desloracell?

Possible Side Effects and Safety Information

The safety profile of Desloracell (desloratadine) is established through clinical trial data and regulatory post-marketing surveillance reports. Adverse reactions are classified by frequency, allowing for a structured understanding of potential effects. The frequency framework categorizes events as Common (reported in adult/adolescent trials at a rate greater than placebo), Very Rare, or Not Known (based on spontaneous post-marketing reports).

Common adverse reactions documented for adults and adolescents include headache, fatigue, and dry mouth. For infants and toddlers (6–23 months), common effects can include fever, diarrhoea, and insomnia.


Regulatory Classification of Adverse Events

Adverse events identified through post-marketing experience are grouped by the physiological system affected (System-Organ Class) and generally fall into the Very Rare or Not Known frequency categories:

System-Organ Class Examples of Documented Effects
Hepatobiliary Disorders Elevations of liver enzymes, hepatitis, jaundice
Cardiac Disorders Tachycardia, palpitations, QT prolongation
Psychiatric Disorders Hallucinations, aggression, depressed mood
Nervous System Disorders Dizziness, somnolence, seizures

Serious Adverse Reactions and Population Notes

Serious adverse reactions officially documented include hypersensitivity reactions (such as anaphylaxis and angioedema), hepatitis, and seizures. Use requires caution in specific populations, particularly patients with severe hepatic impairment or severe renal insufficiency due to the potential for increased systemic exposure. Caution is also advised in the paediatric population, especially those with a personal or familial history of seizures, due to a documented risk of new-onset seizures.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Desloracell (desloratadine) indicates that symptoms associated with overdosage are generally similar to those seen with therapeutic doses, but the magnitude of the effects can be higher.

Overdosage has been associated with specific symptoms, including drowsiness (somnolence), noted in clinical trials involving exposures up to nine times the recommended dose. While high-dose trials did not show clinically relevant severe effects, serious outcomes such as seizures and tachycardia (rapid heart rate) have been reported as adverse events in the regulatory safety profile.

Immediate Emergency Action

Urgent medical attention is required for any suspected overdose. Individuals must immediately call emergency services if the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Contacting a Poison Help line or seeking immediate medical attention is mandated.

Management and Antidote

No specific antidote is known for desloratadine overdose. Management is based on symptomatic and supportive treatment. Regulatory guidance recommends considering standard procedures to remove any unabsorbed drug. Desloratadine and its active metabolite are not eliminated by haemodialysis.

Therapeutic Uses of Desloracell

What Desloracell Treats: Main Uses and Benefits

Desloracell is used in situations involving certain distressing symptoms, supporting patients during difficult episodes by easing distress. The therapeutic support is considered relevant in conditions presenting with systemic or localized discomfort, such as allergic rhinitis (seasonal and perennial) and chronic idiopathic urticaria (hives).

This medication is applied in managing symptoms related to inflammatory or irritative states. It is relevant for managing symptoms that interfere with daily comfort, such as frequent sneezing, profuse runny nose, nasal itching, and severe skin itching (pruritus).

“It is commonly applied when symptoms create noticeable physiological strain and when supportive symptom management is appropriate.”

The medication may assist with maintaining functional stability and routine. Relevant in contexts involving heightened systemic burden, offering sustained support with a generally non-sedating profile, Desloracell contributes to improved comfort during periods of heightened symptoms.


Summary of Symptom Management

Condition Category Symptom Management Focus
Allergic Rhinitis Applied in addressing nasal discharge, sneezing, and ocular irritation.
Chronic Urticaria Applied in addressing the intensity of skin itching and the presence of wheals.
Daily Function Supports general well-being and maintenance of wakefulness.

Regulatory References

  1. European Medicines Agency (EMA) product overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Desloracell

The eligibility for using Desloracell (desloratadine) is strictly defined by regulatory authorities based on age, hypersensitivity, and underlying health conditions.

Contraindications and Absolute Prohibitions

Desloracell is contraindicated and must not be used by patients with a known history of hypersensitivity to the active ingredient, desloratadine, the parent compound loratadine, or any ingredient used in the formulation. Certain tablet formulations are also contraindicated for individuals with rare hereditary problems, such as galactose intolerance.


Age and Organ-Function Eligibility

Population Group Regulatory Status
Adults and Adolescents (≥ 12 years) Use is established.
Children (6 months to 11 years) Use is established (via Oral Solution) in some regions.
Infants (Below 6 months) Use is not established as safety and effectiveness data are insufficient.
Severe Renal/Hepatic Impairment Conditional use in adults due to increased drug exposure. Use is not established in children with these conditions.

Conditional Use and Reproductive Status

Use requires caution in patients with a medical or familial history of seizures. Regarding lactation (breastfeeding), desloratadine is distributed into breast milk; the regulatory direction requires a decision to either discontinue the medicine or discontinue nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Desloracell (desloratadine) is defined by specific pharmacokinetic changes and a caution regarding concomitant substance use, based on government health authority documents.

Pharmacokinetic Interactions

Interacting Substance Category Specific Medicines Interaction Outcome as Documented
Exposure-Modifying Agents Ketoconazole, Erythromycin, Cimetidine, Fluoxetine, Azithromycin Co-administration results in increased plasma concentrations (AUC and Cmax) of desloratadine and its active metabolite.

Regulatory studies found that these documented increases in drug exposure did not result in clinically relevant changes in the overall safety profile.

Pharmacodynamic and Other Interactions

Interacting Substance Regulatory Classification Constraint / Labeled Condition
Alcohol (Ethanol) Caution While a clinical study found no potentiation of performance-impairing effects, post-marketing reports of alcohol intolerance and intoxication prompt a regulatory caution for concomitant use.
Food Intake No Restriction Desloracell may be taken with or without a meal as food does not affect the drug's bioavailability.

Population-Specific Notes

The systemic exposure of desloratadine is officially documented as increased in patients with severe renal impairment and those with hepatic impairment due to altered drug clearance. No mandatory drug-drug administration timing rules or formal contraindicated combinations are listed in the product labeling beyond known hypersensitivity.

Mechanism of Action

How Desloracell Works

Desloracell initiates its action by selectively binding to and modulating specific regulatory receptors located on cell surfaces, a fundamental step that defines its primary pharmacodynamic mechanism. This interaction alters the receptor's conformation and intrinsic activity, which results in a change to the cell's immediate downstream signaling.

Following receptor engagement, the drug influences key intracellular signaling pathways and second messenger systems. By modifying the intensity and duration of these molecular signals, Desloracell results in the dampening of excessive pathway activation and alters the overall amplification of signals within the targeted pathway. This molecular activity translates into a targeted modulation of specific humoral or neural regulatory systems. This action influences the molecular feedback loops that govern overactive physiological processes and maintains a controlled level of mechanistic modulation within the affected systemic pathways.

Dosage and Administration Information

Desloracell is intended for oral administration, utilizing various available formulations that include the film-coated tablet and the oral solution (syrup). The use of the medicine is structured around a once-daily dosing frequency, and administration is permissible with or without a meal. This standardized approach to ingestion simplifies patient compliance.

The standard adult regimen for adolescents and adults (12 years and older) is a single 5 mg dose. Dosage tiers are established for pediatric patients (6 months to 11 years), and the liquid formulation must be accurately measured using a calibrated device to ensure precision. A key population-specific instruction requires the dosage frequency to be modified to 5 mg every other day for adult patients with severe renal or hepatic impairment.

Usage patterns are defined by the patient's condition: treatment for intermittent allergic symptoms may be discontinued when symptoms resolve and reinitiated upon recurrence. For chronic or persistent symptoms, continuous use may be maintained for the duration of the episode.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Desloracell


1. Evidence for Use in Allergic Rhinitis

Research explored the active ingredient of Desloracell primarily using short-term, randomized, controlled trials (RCTs), supplemented by high-level systematic reviews. These studies were structured to explore how measurements of symptoms, such as sneezing, itching, and watery eyes, evolved over a defined time interval. Researchers applied standardized tools to measure patient-reported outcomes describing perceived discomfort, focusing on composite scales like the Total Symptom Score (TSS).

The studies reported measurements of how symptoms evolved in the observed populations during the short trial period. Findings describe patterns observed in the measured outcomes related to physical discomfort and the functional axes of daily living, which were tracked using quality-of-life questionnaires. The available data for certain groups, such as those experiencing severe nasal congestion, remain less comprehensive when compared to other rhinitis symptoms examined in the trials.


2. Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Research examined conditions involving periods of heightened symptoms, specifically chronic idiopathic urticaria (CIU). The active ingredient of Desloracell was observed in these research settings. The studies explored outcomes related to physical discomfort by monitoring the severity and frequency of hives and itch, using standardized tools like the Urticaria Activity Score (UAS).

Research describes patterns related to outcomes capturing phases of heightened symptom activity. What remains uncertain is the need for dose adjustments in some patients to achieve specific measured outcomes; research records discuss this variability. Furthermore, symptom recurrence was observed in some studies after treatment cessation.


3. Long-Term Studies and Durability of Response

The majority of the pivotal clinical trials were designed to examine short-term changes in symptom patterns, with follow-up durations typically ranging from four to six weeks. The existing research provides limited information for long-term outcomes, meaning long-term effects are not fully established. Data for how the measured changes persist over many months or years are insufficient. Consequently, the research does not determine whether an individual will maintain a response or how often symptoms may return over extended periods.


4. Evidence in Specific Patient Populations

Studies have explored outcomes across various age groups. The active ingredient was studied for allergic rhinitis in pediatric populations (starting from 6 years of age) and was also evaluated for hives in children as young as six months. It is crucial to remember that results apply only to the populations studied, and data for other highly specific groups, such as the frail elderly, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Desloracell (FAQ)


Q: How quickly does Desloracell start working?

Studies indicate that the active substance in Desloracell can be measured in the bloodstream within 30 minutes of administration. An antihistaminic effect, which helps relieve symptoms, has been observed in human skin tests starting as early as one hour after a dose. The time to symptom relief can vary between individuals, as noted in official reports.


Q: How long do the effects of Desloracell last?

Regulatory information indicates that Desloracell provides an antihistaminic effect that may persist for up to 24 hours. This duration of effect is consistent with the drug’s official once-daily frequency, as defined in regulatory information.


Q: What does the term 'non-sedating' mean for Desloracell?

Desloracell is described as non-sedating because its structure limits its entry into the central nervous system, meaning it generally causes fewer effects on the brain compared to older allergy medicines. Regulatory documents state that it has no or negligible influence on the ability to drive or use machines for the majority of users.


Q: What is the difference between Desloracell and loratadine?

Official information describes Desloracell (desloratadine) as the major active metabolite of loratadine. This means that after loratadine is taken, desloratadine is the primary substance created by the body that delivers the therapeutic, or symptom-relieving, effect.


Q: Does taking Desloracell affect the results of allergy skin tests?

As with other antihistamines, official regulatory precautions state that Desloracell may suppress the positive skin test reaction to dermal allergens. Use of the medicine must typically be discontinued before skin testing procedures, based on official guidance.


Q: Is Desloracell used for conditions other than allergies, like hives?

Yes, official regulatory indications show that Desloracell is approved for treating the symptoms of both allergic rhinitis (such as hay fever) and the physical symptoms associated with chronic idiopathic urticaria (commonly known as hives).


Q: Does Desloracell have a risk of cardiovascular side effects?

Adverse effects affecting the heart, such as tachycardia (fast heart rate), palpitations, and QT prolongation, have been documented in post-marketing reports. These events have been reported and are categorized as Very Rare or Not Known in the official safety profile.


Q: Can Desloracell affect my ability to drive or operate machinery?

While regulatory studies suggest the medicine has a negligible influence on mental alertness for most people, individual responses can vary. Official documents recommend caution and suggest that individuals should not engage in activities requiring complete mental alertness until they know how the drug affects them.


Q: Is it normal to feel a bit tired after starting Desloracell?

Official safety data lists fatigue, or general tiredness, as a Common adverse reaction for adults and adolescents, meaning it is one of the more frequently reported effects. Somnolence, or drowsiness, is listed as Very Rare or Not Known.


Q: Can Desloracell cause changes in mood or behavior?

Post-marketing reports listed under the Psychiatric Disorders category include effects such as hallucinations, aggression, depressed mood, and abnormal behavior. These effects are categorized as Very Rare or Not Known in the official safety profile.


Q: What should I do if I think I've taken too much Desloracell?

Official regulatory information states that in the event of an overdose, management should involve symptomatic and supportive treatment. Standard measures to remove unabsorbed medicine are listed as being considered procedures. It is noted that Desloracell is not removed by haemodialysis.


Q: Does Desloracell cause weight changes?

Post-marketing safety data includes reports of increased weight and increased appetite. These specific effects are documented under the frequency classification of Not Known according to the European Summary of Product Characteristics (SmPC).


Q: Is Desloracell safe to take during pregnancy?

Based on a large amount of available data, no malformative or fetal toxicity has been indicated. However, official regulatory documents state that, as a precautionary measure, the use of Desloracell is generally advised to be avoided during pregnancy.


Q: Does Desloracell work for all types of allergies?

The medicine is officially indicated for the relief of symptoms associated with allergic rhinitis and chronic idiopathic urticaria (hives). Its official scope is limited to these specific conditions and their documented symptoms.


Q: What are the official restrictions on Desloracell use?

Official restrictions include its contraindication for individuals with a known hypersensitivity (allergy) to Desloracell or its components. Cautions also apply to patients with severe renal or hepatic impairment, those with a history of seizures, and its use during pregnancy is typically advised to be avoided as a precautionary measure.


Q: Does Desloracell treat the cause or the symptoms of allergies?

Desloracell is classified as an antihistamine, which acts by blocking the effects of histamine released during an allergic response. Its official purpose is to provide relief from the symptoms, such as itching and swelling, that are associated with allergic conditions.


Q: How does Desloracell impact the immune system?

The primary mechanism is H1-receptor antagonism, which blocks a key effect of the allergic response. Beyond its primary action, regulatory information indicates the drug may also have documented anti-inflammatory effects by influencing the release of various inflammatory substances.


Q: Can Desloracell interact with psychiatric medications?

Formal studies have been conducted with certain psychiatric medications, such as Fluoxetine. In these specific studies, official documents reported no clinically relevant changes to the overall safety profile, even when increased drug levels were observed. Interactions with other types of psychiatric medications have not been universally documented in formal studies.


Q: Are there any specific patient groups where Desloracell should be used with caution?

Official regulatory documents specify that caution is advised for specific patient groups, including individuals with severe kidney or liver impairment and children who have a personal or family history of seizures.

How should Desloracell be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Desloracell (Desloratadine) to maintain product integrity and ensure safety.

Dosage Form Required Storage Conditions Post-Opening Stability
Tablets Store at or below 30°C. Protect from moisture and light. Keep in original blister packaging. Until the expiry date
Oral Solution Store at room temperature. Protect from light. Do not freeze. Keep the bottle tightly closed. Discard two months after first opening

All forms of Desloracell must be stored out of the sight and reach of children.

Disposal: Unused or expired medication must not be discarded in the household trash or thrown away via wastewater. Disposal must occur according to local regulations or by utilizing authorized pharmaceutical take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Desloracell found in:

A-Z Index: